CTOs on the Move

Elucida Oncology

www.elucidaoncology.com

 
Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Elucida Oncology raised $44M on 01/12/2021

Similar Companies

Norgren Systems

Norgren Systems is a Ronceverte, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pervasis Therapeutics Inc

Pervasis Therapeutics Inc is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genera Energy

Genera Energy provides a robust and integrated biomass supply solution for the advanced biofuels, biopower, and biobased products industries.

Calithera

Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.